Trade Applied Therapeutics Inc - APLT CFD

About Applied Therapeutics Inc

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Applied Therapeutics Inc revenues was not reported. Net loss increased 12% to $105.6M. Higher net loss reflects General and administrative - Balancing increase of 66% to $15.7M (expense), Stock-based Compensation in SGA increase of 55% to $8.4M (expense), Other general & administrative expenses increase of 73% to $5.4M (expense).